NordiNet® International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin®
Phase of Trial: Phase IV
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Somatropin (Primary)
- Indications Dwarfism; Growth disorders; Short stature; Somatotropin deficiency
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 03 Feb 2017 Status changed from recruiting to completed.
- 01 Jun 2016 New trial record
- 04 Apr 2016 Results of subgroup analysis (n=140) presented at The 98th Annual Meeting of the Endocrine Society.